Literature DB >> 1101690

Comparative pharmacologic effects of pilocarpine administered to normal subjects by eyedrops or by ocular therapeutic systems.

V A Place, M Fisher, S Herbst, L Gordon, R Merrill.   

Abstract

Normal volunteers used 1, 2, and 4% pilocarpine eyedrops, three times daily, or ocular therapeutic systems placed in the conjunctival cul-de-sac to control intraocular pressure. The systems continuously release 20 and 40 mug/hour of pilocarpine for one week. Although the amount of drug delivered to the eye from the ocular therapeutic system was one fifth that obtained from the eyedrops, the decrease of intraocular pressure was comparable. The ocular therapeutic systems produced small, constant effects on visual acuity, refractive error, and miosis that did not cause visual handicaps or require correction. The effects of eyedrops on these visual factors were large and varied and produced marked visual handicaps that were not correctable with spectacles. Despite its comparable hypotensive effect in normal subjects, continuous delivery of pilocarpine by means of an ocular therapeutic system elicits less severe side effects than pilocarpine eyedrops.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1101690     DOI: 10.1016/0002-9394(75)90404-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Comparison of the pupillary, refractive, and hypotensive effects of Ocusert-40 and pilocarpine eyedrops in the treatment of chronic simple glaucoma.

Authors:  S E Smith; S A Smith; A I Friedmann; J M Chaston
Journal:  Br J Ophthalmol       Date:  1979-04       Impact factor: 4.638

Review 2.  Rate-controlled drug dosage.

Authors:  J Urquhart
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

3.  Piloplex, a new long-acting pilocarpine polymer salt. B: Comparative study of the visual effects of pilocarpine and Piloplex eye drops.

Authors:  Z Mazor; U Ticho; U Rehany; L Rose
Journal:  Br J Ophthalmol       Date:  1979-01       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.